Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings

With many of the Magnificent 7 stocks reporting earnings the week of October 28, investors’ attention was on technology stocks. But that means you may have overlooked two biopharmaceutical companies that delivered solid earnings reports.   Merck & Co. Inc. NYSE: MRK and The Bristol-Myers Squibb Co. NYSE: BMY beat analysts' estimates on the top and bottom lines. Revenue for both companies was higher than in the same quarter in 2023, but both companies reported lighter year-over-year earnings. For Bristol-Mye ...